Article
The U.S. Food and Drug Administration (FDA) is warning the public about "adverse events" associated with some "permanent" makeup treatments.
Pediatric Melanoma in Review: Providing Considerations for Dermatologists
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Off-Treatment Remission Achieved with Dupilumab for Pediatric AD
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis
Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients